Therapeutic Evaluation of Anjeer (Ficus carica Linn) in Ziabetus Shakri (Type 2 Diabetes)

A randomized, single-blind, standard-controlled clinical trial was conducted to assess the therapeutic efficacy of Anjeer (Ficus carica) in the management of Type 2 Diabetes Mellitus (T2DM), traditionally referred to as Ziabetus Shakri. Sixty confirmed T2DM patients were randomly assigned into two groups: Group A (Test) and Group B (Control), with 30 participants in each. Group A received the investigational drug (Ficus carica) at a dosage of 3 grams twice daily, while Group B was administered Metformin 500 mg (Cipla), one tablet twice daily, over a period of 45 days. The findings demonstrated that the test formulation significantly improved certain subjective symptoms, including fatigue (p<0.001) and unexplained weight loss (p<0.01). However, no statistically significant changes were observed in polyuria, polydipsia, polyphagia, or progressive weakness (p>0.05). Regarding objective parameters, Group A exhibited notable improvements in fasting blood sugar (FBS), postprandial blood sugar (PPBS), urine glucose levels (p<0.01), and glycated hemoglobin (HbA1c) (p<0.05). In contrast, the control group did not show statistically significant changes in FBS and urine glucose (p>0.05). These results suggest that Ficus carica may offer potential as an adjunctive treatment for T2DM, particularly in alleviating specific clinical symptoms and improving glycemic control.